betahistine intranasal (AM-125) / Altamira Therap - LARVOL DELTA

Altamira Therapeutics Provides Investor and Business Update (GlobeNewswire) - "Meanwhile, Altamira is also pursuing the partnering of its other legacy assets, which include several development programs in inner ear therapeutics. Discussions are most advanced regarding AM-125, a nasal spray for the treatment of acute vestibular syndrome, a very frequent type of dizziness. Altamira invested more than $18 million to date and demonstrated proof of concept in a Phase 2 trial. There is no comparable product in the US. The Company expects significant partnering progress during the first half of 2024....The Company has an expanding pipeline of business development projects with potential collaboration partners and expects important progress in 2024. Altamira’s two flagship programs, AM-401 and AM-411, for KRAS-driven cancer and rheumatoid arthritis respectively, serve to demonstrate the technology’s potential and shall be licensed out following the IND (expected for early 2025) or after a Phase 1 trial, at the latest."

Commercial • Financing • IND • CNS Disorders • Immunology • Inflammation • Rheumatoid Arthritis • Vertigo

Efficacy and Safety of Intranasal Betahistine in the Treatment of Surgery-Induced Acute Vestibular Syndrome: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Study. (PubMed, Otol Neurotol) - "Intranasal betahistine may help accelerate vestibular compensation and alleviate signs and symptoms of vestibular dysfunction in surgery-induced AVS. Further evaluation in a confirmatory manner appears warranted."

Journal • P2 data • Surgery • Brain Cancer • Oncology • Ophthalmology • Otorhinolaryngology • Solid Tumor • Vertigo

Targeting serotonin receptor 2B inhibits TGFβ induced differentiation of human vascular smooth muscle cells. (PubMed, Eur J Pharmacol) - "We show that AM1125, a selective 5-HT2B receptor inhibitor, significantly inhibits TGFβ1 induced production of collagen and CTGF...Collectively, the HTR2B/TGF-β1/Phospho-Smad2 pathway plays a critical role in the regulation of VSMCs differentiation. Our findings might serve 5-HT2B receptor as a therapeutic target to limit TGF-β1 induced VSMC differentiation."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Fibrosis • CTGF • TGFB1

TRAVERS: AM-125 in the Treatment of Acute Peripheral Vertigo Following Neurosurgery (clinicaltrials.gov) - P2 | N=124 | Completed | Sponsor: Auris Medical AG | Recruiting ➔ Completed

Trial completion • Otorhinolaryngology • Solid Tumor • Vertigo

TRAVERS: AM-125 in the Treatment of Acute Peripheral Vertigo Following Neurosurgery (clinicaltrials.gov) - P2 | N=118 | Recruiting | Sponsor: Auris Medical AG | Trial primary completion date: Dec 2021 ➔ Mar 2022

Trial primary completion date • Otorhinolaryngology • Vertigo

TRAVERS: AM-125 in the Treatment of Acute Peripheral Vertigo Following Neurosurgery (clinicaltrials.gov) - P2; N=118; Recruiting; Sponsor: Auris Medical AG; Trial completion date: Aug 2021 ➔ Jan 2022; Trial primary completion date: Aug 2021 ➔ Dec 2021

Trial completion date • Trial primary completion date • Otorhinolaryngology • Vertigo • MRI

TRAVERS: AM-125 in the Treatment of Acute Peripheral Vertigo Following Neurosurgery (clinicaltrials.gov) - P2; N=118; Recruiting; Sponsor: Auris Medical AG; Trial completion date: Mar 2021 ➔ Aug 2021; Trial primary completion date: Feb 2021 ➔ Aug 2021

Clinical • Trial completion date • Trial primary completion date • Otorhinolaryngology • Vertigo

TRAVERS: AM-125 in the Treatment of Acute Peripheral Vertigo Following Neurosurgery (clinicaltrials.gov) - P2; N=118; Recruiting; Sponsor: Auris Medical AG; Trial completion date: May 2020 ➔ Mar 2021; Trial primary completion date: Apr 2020 ➔ Feb 2021

Clinical • Trial completion date • Trial primary completion date • CNS Disorders • Oncology • Solid Tumor • Vertigo